PIQRAY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Piqray, and when can generic versions of Piqray launch?
Piqray is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug.
This drug has fifty-eight patent family members in forty-eight countries.
The generic ingredient in PIQRAY is alpelisib. One supplier is listed for this compound. Additional details are available on the alpelisib profile page.
DrugPatentWatch® Generic Entry Outlook for Piqray
Piqray was eligible for patent challenges on May 24, 2023.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 29, 2033. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for PIQRAY
| International Patents: | 58 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 73 |
| Clinical Trials: | 16 |
| Patent Applications: | 830 |
| Drug Prices: | Drug price information for PIQRAY |
| What excipients (inactive ingredients) are in PIQRAY? | PIQRAY excipients list |
| DailyMed Link: | PIQRAY at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PIQRAY
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for PIQRAY
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Columbia University | Phase 1 |
| Stemline Therapeutics, Inc. | Phase 1/Phase 2 |
| Celcuity, Inc. | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for PIQRAY
US Patents and Regulatory Information for PIQRAY
PIQRAY is protected by two US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of PIQRAY is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting PIQRAY
Pyrrolidine-1,2-dicarboxamide derivatives
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF ADULTS WITH HR-POSITIVE, HER-2-NEGATIVE, PIK3CA-MUTATED, ADVANCED OR METASTATIC BREAST CANCER
Pyrrolidine-1,2-dicarboxamide derivatives
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting PIQRAY
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
EXPANSION OF THE INDICATION TO INCLUDE PRE AND PERIMENOPAUSAL WOMEN
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | PIQRAY | alpelisib | TABLET;ORAL | 212526-001 | May 24, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Novartis | PIQRAY | alpelisib | TABLET;ORAL | 212526-002 | May 24, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | PIQRAY | alpelisib | TABLET;ORAL | 212526-001 | May 24, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | PIQRAY | alpelisib | TABLET;ORAL | 212526-003 | May 24, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | PIQRAY | alpelisib | TABLET;ORAL | 212526-002 | May 24, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | PIQRAY | alpelisib | TABLET;ORAL | 212526-001 | May 24, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Novartis | PIQRAY | alpelisib | TABLET;ORAL | 212526-001 | May 24, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for PIQRAY
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Novartis Europharm Limited | Piqray | alpelisib | EMEA/H/C/004804 Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1). |
Authorised | no | no | no | 2020-07-27 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for PIQRAY
When does loss-of-exclusivity occur for PIQRAY?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 3369
Estimated Expiration: ⤷ Sign Up
Patent: 2074
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 09290904
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0918750
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 34819
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 11000504
Estimated Expiration: ⤷ Sign Up
China
Patent: 2149711
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 51738
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 110059
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0160014
Estimated Expiration: ⤷ Sign Up
Cuba
Patent: 000
Estimated Expiration: ⤷ Sign Up
Patent: 110052
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 17078
Estimated Expiration: ⤷ Sign Up
Patent: 20037
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 31537
Estimated Expiration: ⤷ Sign Up
Dominican Republic
Patent: 011000070
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 11010880
Estimated Expiration: ⤷ Sign Up
El Salvador
Patent: 11003853
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 8863
Estimated Expiration: ⤷ Sign Up
Patent: 1100447
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 31537
Estimated Expiration: ⤷ Sign Up
Georgia, Republic of
Patent: 0135991
Patent: 2-CARBOXAMIDE-PYRROLIDINE-AMIDE UREA DERIVATIVES SUBSTITUTED WITH PYRIMIDINE-4-YL, AND USAGE THEREAT TREATMENT OF DISEASES CAUSED BY PHOSPHATIDYL INOSITOL 3-KINASE
Estimated Expiration: ⤷ Sign Up
Honduras
Patent: 11000699
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 56305
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 25884
Estimated Expiration: ⤷ Sign Up
Patent: 000044
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 0976
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 86601
Estimated Expiration: ⤷ Sign Up
Patent: 12502080
Estimated Expiration: ⤷ Sign Up
Jordan
Patent: 21
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 331537
Estimated Expiration: ⤷ Sign Up
Patent: 2020534
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 1556
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 11002597
Estimated Expiration: ⤷ Sign Up
Montenegro
Patent: 284
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 604
Estimated Expiration: ⤷ Sign Up
Netherlands
Patent: 1071
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 0754
Estimated Expiration: ⤷ Sign Up
Nicaragua
Patent: 1100049
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 20037
Estimated Expiration: ⤷ Sign Up
Panama
Patent: 41901
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 110796
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 31537
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 31537
Estimated Expiration: ⤷ Sign Up
San Marino
Patent: 201100019
Estimated Expiration: ⤷ Sign Up
Patent: 01100019
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 476
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 31537
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1100699
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1290844
Estimated Expiration: ⤷ Sign Up
Patent: 110038737
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 60673
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 53206
Estimated Expiration: ⤷ Sign Up
Patent: 1014851
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 11000053
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 4147
Estimated Expiration: ⤷ Sign Up
Uruguay
Patent: 096
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering PIQRAY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Poland | 2331537 | ⤷ Sign Up | |
| Netherlands | 301071 | ⤷ Sign Up | |
| Lithuania | C2331537 | ⤷ Sign Up | |
| San Marino | P201100019 | Composti organici | ⤷ Sign Up |
| Jordan | 3121 | مشتقات 1 - ((5-هيتيرورلثيازول-2-يل) أمينوكاربونيل) بيروليدين-2-كربوكساميد كمثبات الفوسفاتديلينوسيتول 3-كيناس (PI3K) مفيدة في علاج الأمراض التصاعدية (1-((5-HETEROARYLTHIAZOL-2-YL)AMINOCARBONYL)PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES) | ⤷ Sign Up |
| South Korea | 101290844 | ⤷ Sign Up | |
| Ecuador | SP11010880 | COMPUESTOS ORGÁNICOS | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PIQRAY
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2331537 | 2020C/547 | Belgium | ⤷ Sign Up | PRODUCT NAME: ALPELISIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/20/1455 20200728 |
| 2331537 | PA2020534 | Lithuania | ⤷ Sign Up | PRODUCT NAME: ALPELISIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/20/1455 20200727 |
| 2331537 | CR 2020 00054 | Denmark | ⤷ Sign Up | PRODUCT NAME: ALPELISIB ELLER ET FARMACEUTISK ACCEPTABELT SALT HERAF; NAT. REG. NO/DATE: EU/1/20/1455 20200728; FIRST REG. NO/DATE: CH 67359 20200324 |
| 2331537 | C20200034 00362 | Estonia | ⤷ Sign Up | PRODUCT NAME: ALPELISIIB;REG NO/DATE: EU/1/20/1455 28.07.2020 |
| 2331537 | 2020037 | Norway | ⤷ Sign Up | PRODUCT NAME: ALPELISIB ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV; REG. NO/DATE: EU/1/20/1455 20200810 |
| 2331537 | PA2020534,C2331537 | Lithuania | ⤷ Sign Up | PRODUCT NAME: ALPELISIBAS ARBA JO DRUSKA; REGISTRATION NO/DATE: EU/1/20/1455 20200727 |
| 2331537 | 2020/048 | Ireland | ⤷ Sign Up | PRODUCT NAME: ALPELISIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/20/1455 20200728 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
